Our analysis displays the predictive value of the above-mentioned on-treatment risk model based on CRP kinetics and the early onset of TRAEs, which can be easy to implement in clinical practice at no extra cost to optimize treatment monitoring in patients with advanced RCC. The gene discussed is CRP; the disease is renal cell carcinoma.